**VASILIS VASILIOU, Ph.D.**

# Curriculum Vitae

**GENERAL/PERSONAL INFORMATION**

Work Address: Department of Environmental Health Sciences,

Yale School of Public Health,

60 College Street, Rm. 511

PO Box 208034

New Haven, CT 06520-8034

Phone : (203) 737 8094. FAX : (203) 737 6023

E-mail: vasilis.vasiliou@yale.edu

URL: [www.aldh.org](http://www.aldh.org)

Home Address: 1158 Jennifers Drive

Guilford, CT

Phone: (303) 730-3998

*Marital Status*: Married (November 24, 1990)

*Spouse Name*: Maria Vasioti

*Children*: Konstantinos, Melpomene, Panorea, Zisis, and Ares

**EDUCATION**

1979-1983 **B.S., Chemistry,** School of Natural Sciences, University of Ioannina, Greece.

1983-1988 **Ph.D., Biochemistry,** Medical School, University of Ioannina, Greece.

1988-1990 **Postdoctoral training in Pharmacology**, University of Ioannina, Greece.

* 1. **Postdoctoral training in Molecular Toxicology & Pharmacogenetics**, University of Cincinnati, OH.

2015 **Masters of Arts Privatim,** Yale University (honorary degree).

#### ACADEMIC APPOINTMENTS

2018- **Susan Dwight Bliss** **Professor of Epidemiology**, Yale School of Public Health, Yale School of Medicine, New Haven, Connecticut.

2014- **Professor and Chair** (primary appointment tenured),Department of Environmental Health Sciences, Yale School of Public Health, Yale School of Medicine, New Haven, Connecticut.

2014- **Professor** (secondary appointment), Department of Ophthalmology & Visual Sciences, Yale Medical School, New Haven, Connecticut.

2007-2014 **Professor** (primary appointment tenured),Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.

2008-2014 **Professor** (secondary appointment), Department of Ophthalmology, Medical School, University of Colorado Health Sciences Center, Denver, Colorado.

2001-2007 **Associate Professor,** Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.

2001- 2014 **Director** of the Molecular Toxicology and Environmental Health Sciences Program, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.

2000- 2001 **Associate Director** of the Molecular Toxicology and Environmental Health Sciences Program, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.

1996-2001 **Assistant Professor,** Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.

1994-1995 **Research Associate**, Laboratory of Molecular Toxicology, Department of Environmental Health, University of Cincinnati Medical Center, Ohio, USA.

**PROFESSIONAL EXPERIENCE**

2017-2018 Member of the National Academies of Sciences, Engineering, and Medicine’s Committee to Review Report on Long-Term Health Effects on Army Test Subjects.

2016- Discusant of EPA’s Integrated Risk Information System (IRIS) Toxicological Review of Ethyl tert-Butyl Ether (ETBE).

2005-2006 **Guest Scientist**, Laboratory of Molecular and Developmental Biology, National Eye Institute, NIH, Bethesda, MD.

1991-1993 **Postdoctoral Fogarty Fellow**, Laboratory of Molecular Toxicology, Department of Environmental Health, University of Cincinnati Medical Center, Ohio, USA (Mentor: Dan W. Nebert).

1989-1990 **Service in Greek Army** as a Postdoctoral Research Fellow, Department of Pharmacology, Medical School, University of Ioannina, Greece (Mentor: Marios Marselos).

1984 **Visiting Fellow** (3 months), Departments of Physiology and Pharmacology & Toxicology, University of Kuopio, Finland (Mentors: Osmo Hanninen and Matti Lang).

**TEACHING**

**Past (School of Pharmacy, Graduate School and School of Medicine, University of Colorado)**

Principle of Drug Action (Pharmacogenetics) for Pharmacy and PharmD students

Toxicology for Pharmacy students (1997-2000)- (Course Coordinator 2r course)Clinical Sciences Foundation: Organ and Clinical Toxicology 2000-2014 (8 hrs and Course Director).

Graduate Toxicology Core Course I (2000-2014) – 3 credits, (2 hrs)

Graduate Toxicology Core Course II (2000-2014) – 3 credit (4 hrs).

Graduate Drug Metabolism and Pharmacogenetics (1998-2014)- 3 credits (8 hs plus coordination)

Instructional Methods 2 (P2) (Course co-ordination)

Graduate Course in Principles of Toxicology. Molecular and Biochemical Mechanisms (1993-2000)

Graduate course in Organ Systems Toxicity (2 credits). Responsible for 6 hrs.

Graduate course in Occupational Toxicology (2 credits). Responsible for 4 hrs.

Graduate Course in Cancer Biology (2 credits). Responsible for 2hrs.

Graduate Course in Pharmacology (3cr). Responsible for 2 hrs.

**TEACHING**

**Current (Yale School of Public Health)**

Public Health Toxicology Course for MPH and PhD students (2016-2017)

**ADVISING**

**MPH Students (at Yale School of Public Health)**

Nathan Kloczko, Girish Motwani, 2015-2016; Lyndsay Gavin, Dan Huang, Alaina Perkins, Emma Ryan2016-2017; Nina Hatch, Hongwei Song, 2017-2018.

**ADVISING**

## Ph.D. Students directed (at University of Colorado)

Heather Marks-Hull (Toxicology, 1996), M.S. awarded 1997 (Advisor).

Tia Estey (Pharm. Sciences), PhD. Awarded in 2007 (Co-Advisor).

Natalie Lassen (Toxicology Program), Ph.D. Awarded 2007 (Advisor).

Miriam Cantore (Pharmacology, Firenze, Italy), Ph.D. Awarded in 2009 (Co-Advisor).

Satori Waddle (Toxicology Program), Ph.D. Awarded in 2010 (Advisor).

William Black (Toxicology Program), Ph.D. Awarded in 2011(Advisor).

Gurav Mehta (Toxicology Program), MS Awarded in 2011 (Advisor).

Brocker Chad (Toxicology Program), Ph.D. Awarded in 2012 (Advisor).

Vindhya Koppaka (Toxicology Program), Ph.D. Awarded in 2013 (Advisor).

Surendra Singh (Toxicology Program), Ph.D. Awarded in May 2014 (Advisor).

Brian Jackson (Toxicology Program), Ph.D. Awarded in 2015 (Advisor).

Claire Heit (Toxicology Program), Ph.D. Awarded in 2016 (Advisor).

**Ph.D. Students directed (Yale)**

Yewei Wang (EHS) (Advisor 2017-)

Becky Bely Byler (Enginnerining) (Co-Advisor 2017-)

Brian Thompson (EHS) (Advisor 2018-)

Emily Davidson (EHS) (Advisor 2018-)

## Postdoctoral Fellows - Past

Tomas Ziegler, 1999-2001; Current, Research Scientist at Geological Survey, Denver Colorado.

Jaqueline Wallisser, 2000-2001; Current Study Director, Safety Pharmacology at Covance Laboratories, Madison, Wisconsin.

Rizwan Manzer, 2001-2002; Current, Research Associate at National Jewish Hospital, Denver Colorado.

Manolis Merkouris, 2000-2003; Current, Research Scientist at Democritus Res. Institute, Athens Greece.

Aglaia Pappa, 2000-2004; Current, Assistant Professor, Department of Molecular Biology and Genetics Democritus University of Thrace, Greece ([apappa@mbg.duth.gr](mailto:apappa@mbg.duth.gr)).

Dimitrios Stagos, 2007-2009; Current, Assistant Professor, University of Thessaly, Greece. ([stagkos@med.uth.gr](mailto:stagkos@med.uth.gr)).

Akiko Matsumoto, 2009-2011, Current, Assistant Professor, Saga University, Japan, [matsumoa@cc.saga-u.ac.jp](mailto:matsumoa@cc.saga-u.ac.jp).

Hongbin Dong, 2013- 2016 ([hongbing.dong@yale.edu](mailto:hongbing.dong@yale.edu)), University of Dayton.

Stephanie Marshall, 2015-2017 ([Stephanie.marshall@yale.edu](mailto:Stephanie.marshall@yale.edu))

Surendra Singh, 2015-2018 ([surendra.singh@yale.edu](mailto:surendra.singh@yale.edu))

**Current**

Ying Chen, 2009-2010; Current, Research Scientist Yale School of Public Health ([ying.chen@yale.edu](mailto:ying.chen@yale.edu))

Georgia Charkoftaki, 2015- Research Scientist Yale School of Public Health ([Georgia.Charkoftaki@yale.edu](mailto:Georgia.Charkoftaki@yale.edu))

Yewei Wang, 2015- ([yewei.wang@yale.edu](mailto:yewei.wang@yale.edu))

**Junior Faculty Development**

Career development co-mentor in Dr. Aquilante’s K23 award (Now Associate Professor, University of Colorado).

Andrew Monte, Assistant Professor, Emergency Medicine & Medical Toxicology, University of Colorado Denver, 2011-present. Co-Mentor in his K23 award 2014-2018.

Ying Chen, Associate Scientist, Department of Environmental Health Sciences, Yale School of Public Health, 2011-present, Mentor (K01 award 2016-2020).

**Graduate Student Committees - University of Colorado**

Michail Panagiotidis (Toxicology), Ph.D. in 2004 (Chair of the Advisory committee).

John Reichard (Toxicology), Ph.D. in 2004 (Member of the Advisory Committee).

Brante Sampey (Toxicology), Ph.D. in 2005 (Member of the Advisory Committee).

Kariya Chirag (Toxicology), Ph.D. in 2007 (Chair of the Advisory Committee).

Dan McShan (Bioinformatics), Ph.D. candidate (Member of the Advisory Committee).

Srirupa Roy (Toxicology), Ph.D. in 2008 (Member of the Advisory Committee).

Hongfei Zhou (Toxicology), Ph.D. 2010 (Member of the Advisory Committee).

Becky Smathers (Toxicology), Ph.D. candidate (Member of the Advisory Committee).

Samiha Mateen (Toxicology), Ph.D. In 2012 (Member of the Advisory Committee).

James Galligan (Pharmacology) Ph.D. in 2012 (Member of the Advisory Committee).

Swetha Inturi (Toxicology), Ph.D. in 2013 (Member of the Advisory Committee).

Shrotriya, Sangeta (Toxicology), Ph.D. in 2013 (Chair of the Advisory Committee).

Derry Molly (Toxicology), Ph.D. in 2013 (Chair of the Advisory Committee).

**Undergraduate researchers**

Itay Melamed, (MD student), summer student, 1997; Scott Ostriker (4th year Pharmacy student),1996-1997; Lumunita Chang (4th year Pharmacy student), 1999; Alison Veto (UCD`), 2001-2002; 2004; Qui Trong, (UCD), 2002-2004; Phil Weston (UC) 2004-2005; Stella Polycarpou (DU), 2011-2012; Chris Carpenter 2012-2014; Melpomene Vasiliou (CU) 2013-present; Fay Walker (CU) 2014.

**High School Students**

Chris Carpenter 2009-2011; Konstandinos Vasiliou, 2099-2012; Ayathi Apostolopoulos, 2011; Sarah Carpenter, 2011-2012; Melpomene Vasiliou, 2011-2013; Karan Agarwal, 2013; Jared Alswang, 2012-2013; Antonia Papadima (summer 2017).

**ADMINISTRATIVE ACTIVITY AND UNIVERSITY SERVICE**

Yale School of Public Health Committees

Member Appointments & Promotions Committee (2014-present).

Member, Executive Committee of the Climate Change and Health Initiative (2015-present).

Chair and Member of the Stolwijk Fellowship Committee (2014-present).

Curriculum Revision Committee (2017)

Yale Comprehensive Cancer Center

Member, Shared Resource Oversight Committee (2015-present).

Member, Developmental Therapeutics (2014-present).

Yale Campus-Wide

Member of the Scientific Advisory Board Yale Tobacco Centers on Regulatory Science (TCORS).

UCAMC-School of Pharmacy (1996-2014)

Member of the DOPS Space Committee (1996-1999).

Ethics Committee (1999-2002).

New Curriculum Design, Basic Sciences Course, (1998).

Development of the new curriculum for the Toxicology Graduate Program (2001).

Associate Director of the Toxicology Graduate Program (2000-2001).

Director of the Toxicology Graduate Program (2001-present).

Member of the DOPS SOP APT committee (2004-2005; 2007-2008).

Adhoc member of the DOCP (SOP) APT committee (2006-2007).

Chair of the Clinical/Translational Search Committee (2007).

Dean’s Review APT Committee (2008-2011).

Chair of DOPS/SOP APT committee (2011-2013).

Dean’s Review APT Committee, Chair (2013-2014).

Associate Dean for Research Advisory Committee (2014).

UCAMC-Campus-wide (1996-2014)

New Research Building Committee (1996).

Resource Needs, Infrastructure, and Development Task Force (2007).

Member of the Search Committee for Director of Research (Department of Ophthalmology (2007).

Graduate School Dean Search Committee (2009-2010).

Environmental Toxicologist Search Committee, Dept of Biology, UCD (2009).

**SPECIAL ASSIGNMENTS**

DOPS Toxicology Program Seminar Series (1998-2003, 2005-2008).

Chair of Toxicology subcommittee for changes in the Graduate Curriculum (2000).

**MEBER OF PROFESSIONAL ORGANIZATIONS**

The Sociatey of Toxicology (SOT)

The Association for Research in Vision and Ophthalmology (ARVO)

The American Society of Human Genetics (ASHG)

The International Society for Developmental Origins of Health and Disease (DOHAD)

**SERVICE IN PROFESSIONAL ORGANIZATIONS**

Vice-President of MWSOT Regional Chapter (2007-2008).

President of MWSOT Regional Chapter (2008-2009).

Member of the Career Resource and Development Committee of SOT (2009-2012).

Councilor Mechanism Specialty Section of SOT (2010-2012).

Councilor Ocular Toxicity Specialty Section of SOT (2010-2012).

VP-Elect Mechanism Specialty Section of SOT (2012-2013).

Vice President Mechanism Specialty Section of SOT (2012-2013).

President Mechanism Specialty Section of SOT (2013-2014).

Past President Mechanism Specialty Section of SOT (2014-2015).

**AWARDS, HONORS**

1984 Research Scholarship, University of Kuopio, Finland.

1991-1993 International Research Fellowship, Fogarty International Center, NIH.

1998- IUPAC-IUBMB JBN ALDH Gene Nomenclature Committee.

2001 Teacher of the Year Award (selected by the Pharmacy First Professional Year Class).

2006 Travel Award ISBRA.

2011 Dean’s Mentoring Award, University of Colorado AMC Graduate School.

2012 Travel Award ISBRA.

2013 John and Barbara Shell Prize for Excellence in Research and Graduate Education.

2014 Faculty Sponsor Award, University of Colorado AMC Graduate School.

**INVITED SPEAKER IN MEETINGS**

1. Enzymology and Molecular Biology of Carbonyl Metabolism 6, June 1992, Dublin, Ireland.
2. Enzymology and Molecular Biology of Carbonyl Metabolism 7, June 1994, New Palmerston, New Zealand.
3. "Workshop on Drug Metabolism and Toxicity in Balkan Countries", October 1995, Ioannina, Greece.
4. Enzymology and Molecular Biology of Carbonyl Metabolism 8, July 1996, Deadwood, SD, U.S.A.
5. The Midwest Cytochrome P-450 Symposium, September 1997, Purdue, Indiana, U.S.A.
6. Enzymology and Molecular Biology of Carbonyl Metabolism 9, July 1998, Varallo Sesia, Italy
7. 15th Annual Meeting of the Mountain West Chapter of the Society of Toxicology, October 1997, Taos, New Mexico, U.S.A.
8. 17th Annual Meeting of Mountain West Chapter of the Society of Toxicology, September 1999, Breckenridge, Colorado, U.S.A.
9. Enzymology and Molecular Biology of Carbonyl Metabolism 10, July 2000, Taos, NM, U.S.A.
10. Symposium speaker, 40th Annual Society of Toxicology Meeting, March 2001, San Francisco, CA, U.S.A.
11. Symposium speaker at the ISSX 2003.
12. Symposium speaker, 3rdAnnual Meeting of the International Society of Pharmacogenomics, October 1-5 2004, Santorini, Greece.
13. 22nd Annual Meeting of Mountain West Chapter of the Society of Toxicology, September 2004, Park City, Utah, U.S.A.
14. Enzymology and Molecular Biology of Carbonyl Metabolism 11, July 2004, Burlington, VT, U.S.A.
15. Symposium speaker and Co-Clair, [ISBRA 2006 World Congress on Alcohol Research, September 2006, Sydney, Australia](http://www.isbra2006.com/).
16. Symposium speaker and Co-Chair, XVII International Congress of Eye Research, November 2006, Buenos Aires, Argentina.
17. “The Protective Role of ALDH3A1 and ALDH1A1 against Ocular Damage”, Pacific Ocular Regenerative Biology Conference XII, September 16-19, 2007, Laguna Beach, CA, USA
18. "Non-P450 alcohol and aldehyde metabolizing enzymes" Gordon Conference on “DRUG METABOLISM**”,** July 8-13, 2007 Holderness School Holderness, NH, USA.
19. Symposium speaker, RSA/ISBRA joint meeting, June-July 2008, Washington, DC, USA.
20. Golden Helix Symposium, “Pharmacogenomics: Paving the path to personalized medicine”, October 15th-17th, 2009, Athens, Greece.
21. Symposium speaker, Global Hellenic Medical & Biosciences Network (GHMBN), September 3-5, 2009, Lagonisi, Athens, Greece.
22. Symposium speaker, ESBRA meetings, June 2009, Helsinki, Finland.
23. Symposium speaker, ISER meeting, July 2010, Montreal, Canada.
24. Symposium speaker, CLAO and Eye and Contact Lens Symposium on Ultraviolet Radiation and its Effects on the Human Eye, September 2010, Las Vegas, NV, USA.
25. Symposium speaker, *2nd Asia Cornea Society Biennial Scientific Meeting, December 2010, Osaka, Japan.*
26. Symposium speaker, Satellite Meeting: Cornea Research Conference, *December 2010, Osaka, Japan.*
27. Enzymology and Molecular Biology of Carbonyl Metabolism 16, July 201, Ploen, Germany.
28. Symposium speaker, ISER meeting, July 2012, Berlin, Germany.
29. Symposium speaker, ISBRA meetings, September 2012, Sapporo, Japan.
30. Symposium speaker, 18th North American ISSX Meeting, October 2012, Dallas, TX.
31. Symposium speaker, 5th Pan Arab Human Genetics Conference 2013, November 2013, Dubai, United Arab Emirates.
32. The 17th International Conference on Enzymology and Molecular Biology of Carbonyl Metabolism, July 2014, Poconos, PA, U.S.A.
33. Symposium speaker, The 50th Congress of the European Societies of Toxicology (EUROTOX). Edinburgh, UK September 2014
34. Symposium Speaker, 10th International Symposium on Alcoholic and Pancreatic Diseases and Cirrhosis, Chile, September 2015
35. The 18th International Conference on Enzymology and Molecular Biology of Carbonyl Metabolism, Barcelona Spain, July 2016.
36. Symposium speaker, ISER Congress, September 2016, Tokyo, Japan.
37. Seminar Speaker, Fall/Winter 2016-2017 Pharmacology Seminar Series, Weill Cornell Medicine, December 2016, New York, NY
38. Symposium speaker, Gordon Research Conference, Alchohol-Induced End Organ Diseases-“Metabolic Reprogramming and Molecular Mechanisms of Tissue Injury by Alcohol, March 2017, Ventura, CA.
39. Symposium speaker, Annual RSA Scientific Meeting, Denver Colorado, June 2017.
40. **Symposium Speaker, Metabolomics in Translational Research’**, Waters Tecnonogy Summit, Georgetown University, July 2017.
41. Plenary Lecture, ESBRA Congress, October 2017, Herakleion, Greece, October 2017.
42. Symposium speaker, ESBRA Congress, October 2017, Herakleion, Greece, October 2017.
43. Symposium speaker, 100 Years of Ocular Sulfur Mustard: Models, Mechanisms and Therapeutics) Monday, 20 November 2017.
44. Kenote speaker, 1st Zayed Center Genomic Medicine Workshop & the 20th Golden Helix Pharmacogenomics Day, College of Medicine and Health Sciences, Tawam Campus, Al-Ain, UAEU, 2 February 2018.
45. Kenote speaker, UAEU Research and Innovation Conference 2018, Future Engineering and Well-being of UAE, College, College of IT , Tawam Campus, Al-Ain, UAEU, 5 February 2018.
46. Keynote speaker, China-ASEAN Heath Youth Forum, The 2nd China ASEAN Forumon Health Cooperation:Towardsa Health Silk Road, Nanning, Guanxi, China, September 19-21, 2018.

**INVITED SEMINARS**

1. Induction of Aldehyde Dehydrogenases by Chemical Carcinogens. Department of Physiology, University of Kuopio, Finland, September 20, 1990.
2. The mouse [*Ah]* Gene Battery: Positive and Negative Control of Gene Expression. University of Ioannina Medical School, July 16-1992.
3. Aldehyde dehydrogenase gene expression: an example of positive and negative regulation. International Agency for Research on Cancer, Lyon, France, October 6, 1993.
4. Organization and Characterization of the Murine Cytosolic TCDD-inducible Aldehyde Dehydrogenase Gene. University of Ioannina Medical School, October 15, 1993.
5. Murine Dioxin-Inducible Class 3 Aldehyde Dehydrogenase: Regulation of Gene Expression. Environmental Toxicology Center, University of Wisconsin, U.S.A., March 31, 1994.
6. Aldehyde Dehydrogenases and Environnemental Oxidative Stress. Center for Environmental Genetics, University of Cincinnati Medical Center, U.S.A., April 11, 1995.
7. Negative Regulation of the [Ah] Gene Battery: An Update. The 1997 Midwest Cytochromes P450 Symposium. Purdue University, West Lafayette, Indiana, U.S.A., September 25-26, 1997.
8. Polymorphisms of Human Alcohol and Aldehyde Dehydrogenases. Toxicology Program, University of Cincinnati Medical Center, Cincinnati, Ohio, U.S.A., March 1, 2000.
9. Role of Aldehyde Dehydrogenases in Endogenous and Xenobiotic Metabolism. Veterans Administration Medical Center, University of Southern California, Los Angeles, California, U.S.A., September 20, 2000.
10. Mouse *Aldh3a1*: Tissue-specific and Inducible Gene Expression. Laboratory of Molecular and Developmental Biology, National Eye Institute, NIH, Bethesda, Maryland, U.S.A., October 3, 2000.
11. The Role of Aldehyde Dehydrogenases in Metabolism. Laboratory of Metabolism, National Cancer Institute, NIH, Bethesda, Maryland, U.S.A., October 5, 2000.
12. Polymorphisms of the Human Aldehyde Dehydrogenases: Consequences for Drug Metabolism and Disease. Toxicology Program, Colorado State University, Fort Collins, Colorado, U.S.A. September 17, 2000.
13. Toxicologic Importance of the Human Aldehyde Dehydrogenases: From Alcohol to Chemotherapeutic Agents. Presentation on the Symposium on “Pharmacogenetics and Drug Metabolism” at the 40th Annual Society of Toxicology Meeting, March 2001.
14. Polymorphisms of the Human Aldehyde Dehydrogenases: Consequences for Drug Metabolism and Disease. Medical School University of Ioannina, Greece, April 12, 2001.
15. Multiple Protective Roles of the Corneal ALDH3A1 Against Oxidative Damage. University of Texas Health Center at Tyler, Tyler, Texas, U.S.A., August 6, 2002.
16. Protective Role of Corneal Enzymes to Free Radical Oxidative Damage. “Free Radicals in Medicine and Biology Seminar Course” (Colorado Oxygen Radical Society), December 6, 2002.
17. Aldehyde dehydrogenases protect against oxidative damage. Department of Biochemistry and Biotechnology, University of Thesally, Larissa, Greece, April 1, 2003.
18. Aldehyde dehydrogenases protect against oxidative damage. Department of Biology, Aristoteleio University, Thessalonica, Greece, April 3, 2003.
19. Protective Role of ALDH3A1 Against Oxidative Damage. Department of Environmental Health, University of Cincinnati Medical Center, Cincinnati, OH, May 28, 2003.
20. Protective Role of Corneal ALDHs Against Oxidative Damage, National Eye Institute, NIH, Bethesda, MD, December 11, 2003.
21. Multiple roles of aldehyde dehydrogenase 3A1 (ALDH3A1), National Eye Institute, NIH, Bethesda, MD, June 2004.
22. The role of ALDHs in the corneal epithelium, University of Washington, Seattle, WA, February 2004.
23. Protective Roles of Corneal ALDHs against Oxidative Damage, University of Texas Medical Branch, Galveston, TX, December 2004.
24. The Role of Aldehyde Dehydrogenases In Metabolism And Cellular Responses To Oxidative And Osmotic Stress, Department of Experimental medicine and Oncology, University of Turin Italy, April 2005.
25. Corneal Crystallins as a Cellular Response to Oxidative Stress, Department of Pharmacology, University of Florence, April 2005.
26. Cellular Responses to Oxidative and Osmotic Stress, Department of Biochemistry and Molecular Biology, University of Louisville, KY, May 2005.
27. Corneal Crystallins and Cellular Responses to Oxidative Damage, Department of Ophthalmology, Medical University of South Carolina, SC, May 2005.
28. Aldehyde Dehydrogenases and Oxidative Stress, Laboratory of Kidney and Electrolyte Metabolism, NHLBI/NIH, Bethesda, MD, November 2005.
29. Role of Aldehyde Dehydrogenases in Metabolism and Cellular Response to Oxidative and Osmotic Stress, NEI/NIH, Bethesda, MD, December 2005.
30. Polymorphisms of Aldehyde Dehydrogenases: Consequences for Drug Metabolism and Disease, Department of Pharmacology and Physiology, The George Washington University Medical Center, April 2006.
31. Role of Aldehyde Dehydrogenases in Metabolism and Oxidative Stress, NIAAA/NIH, Bethesda, MD. April 2006.
32. Diverse Functions of Corneal Crystallins, Department of Ophthalmology, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, May 2006.
33. Novel and diverse functions of Corneal ALDH3A1, Department of Molecular Medicine, Harbor-UCLA Medical Center, Los Angeles, CA, January 2007.
34. Cataract phenotype and oxidative damage in *Aldh3a1*- and *Aldh1a1*-null mice. Department of Ophthalmology, University of California Irvine, Los Angeles, CA, January 2007.
35. Role of ALDHs against oxidative damage. Dipartimento Medicina ed Oncologia Sperimentale, University of Turin, Turin. Italy, June 2007.
36. The Role of Corneal Crystallins in the Physiology and the Pathophysiology of the Eye. Department of Ophthalmology, Medical University of South Carolina, SC, March 2008.
37. The role of aldehyde dehydrogenases in metabolism and disease, University of Kuopio, Finland, June 2009.
38. The Role Of Aldehyde Dehydrogenases In Metabolism And Disease, Institute of Occupational Health, Helsinki, June 2009.
39. The Role of Aldehyde Dehydrogenases in Drug Metabolism, Metabolic Disease and Cancer Stem Cells, UCLA, Los Angeles, April 2010.
40. Crystallins and Corneal Transparency, Distinguished Lecture Series, Cleveland Clinic, Cole Eye Institute, April 2010.
41. Aldehyde Dehydrogenases: From Metabolic Disease to Cancer Stem Cells, University of Vanderbilt, USA, November 2010.
42. Aldehyde Dehydrogenases: From Metabolic Disease to Cancer Stem Cells, Kitakyushu University, Japan, December 2010.
43. Aldehyde Dehydrogenases: From Inherited Metabolic Diseases to Stem Cells and Cancer, Grand Rounds in Clinical Genetics and Metabolism, Children’s Hospital, University of Colorado Denver, January 12, 2011.
44. Aldehyde Dehydrogenases and Cancer Stem Cells, Pathology Grand Rounds, University of Colorado Denver, January 2011.
45. Aldehyde Dehydrogenases: From Metabolic Disease to Cancer Stem Cells. Lovelace Respiratory Research Institute, Albuquerque, February 2011.
46. Aldehyde Dehydrogenases: From Corneal and Lens Crystallins to Cancer Stem Cells. Jules Stein Eye Institute at UCLA, June 2011.
47. Systems Biology of GSH-Mediated Redox Sensing in Alcoholic Liver Disease, NIAAA/NIH, June 2012.
48. Aldehyde Dehydrogenases: Eye Crystallins to Metabolic Diseases and Cancer Stem Cells, Saga University, Japan, September 2012.
49. Aldehyde Dehydrogenases: Eye Crystallins, Metabolic Diseases and Cancer Stem Cells, The University of Texas Medical Branch at Galveston, October 2012.
50. Aldehyde Dehydrogenases as Potential Therapeutic Agents, University of Colorado Cancer Center Seminar Series, 2012.
51. Aldehyde Dehydrogenases: From Metabolic Diseases and Cancer Stem Cells, Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia, November 2013.
52. Aldehyde Dehydrogenases in Human Health and Disease, Research Centre King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, November 2013.
53. Aldehyde Dehydrogenases: From Crystallins to Stem Cells, SUNY Downstate Medical Center, Brooklyn, NY, February 2014.
54. Aldehyde Dehydrogenases In Cancer: Critical Players Rather Than Stem Cells Markers, Center of Excellence in Environmental Toxicology (CEET) at the University of Pennsylvania, PA, April 2015.
55. Interplay Between Alcohol and Glutathione in Obesity and Diabetes, University of Louisville Diabetes and Obesity Center, Louisville, KY, November 2015.
56. Alcohol and Antioxidants in Obesity and Diabetes, University of North Carolina Nutrition Research Institute, Kannapolis, NC, March 2016.
57. Department of Environmental Health Sciences at Yale School of Public Health: A Vision for the Future. National Institutes of Environmental Health Sciences, NIH, Research Triangle Park (RTP), NC, March 2016,
58. Toxicology Today, University of Larissa, Larissa, Greece, March 2016.
59. Systems Approaches for Environmental Health Research, Chinese NIEHS, August 2016.
60. Metabolomics in Environmental Health Research, Chinese CDC August 2016.
61. Aldehyde dehydrogenases in cancer and cancer stem cells,Seminar Speaker, Fall/Winter 2016-2017 Pharmacology Seminar Series, Weill Cornell Medicine, New York, NY, December 2016.
62. Aldehyde Dehydrogenases in Cancer Stem Cells: Molecular Mechanisms and Drug Development, University of Connecticut, May 2017.
63. Systems Approaches for Environmental Health Sciences in the 21st Century: Metabolomics and the Exposome, Zejiang University, May 2017.
64. Aldehyde dehydrogenases (ALDH) and glutathione (GSH) are key-players in metabolic disease and cancer stem cells, Department of Public Health, College of Political, Administrative and Communication, SciencesBabes-Bolyai University, Romania, July 2017.
65. Systems Approaches for Environmental Health Sciences in the 21st Century, Department of Public Health, College of Political, Administrative and Communication Sciences, Babes-Bolyai University, Romania, July 2017.
66. Genomics In Public Health Surveillance: From Deadly Viruses To Disease Susceptibility and Environmental Exposures, "1st Zayed Center Genomic Medicine Workshop & the 20th Golden Helix Pharmacogenomics Day”, UAE, Feb 2018.

**SOCIETY MEMBERSHIPS**

Society of Toxicology (SOT) since 1996

Mountain West Chapter of Society of Toxicology (MW SOT), 1996-2014

The Association for Research in Vision and Ophthalmology (ARVO), since 1998

Human Genome Organization (HUGO), since 2010

American Society of Human Genetics, since 2011

International Society for Environmental Epidemiology (ISEE), since 2017

International Society for Biomedical Research on Alcoholism (ISBRA), since 2000

International Society for Eye Research (ISER), since 2008

European Society for Biomedical Research on Alcoholism (ESBRA), since 2000

**GRANT/RESEARCH ACTIVITY**

**Current support**

* Mouse Models and Metabolomics Tools to Investigate Alcohol Metabolism and Tissue Injury, 2R24AA022057-07A1 (Vasiliou) NIH/NIAAA, Total direct costs: 1,575,871, 09/20/2018-08/31/2023.
* Mouse Models for Alcohol Metabolism and Tissue Injury; 3R24AA022057-06S1 (PI Vasilis Vasiliou), NIH/NIAAA, Total direct costs: $59,000. 7/6/2017-1/31/2019
* Novel Role of Corneal Crystallins as Modulators of Cell Growth and Transparency 2R01EY017963-06A1 (PI Vasilis Vasiliou), NIH/NEI Total direct costs: $883,187, 05/01/2017-04/30/2020.
* Novel Role of Corneal Crstallins as Modulators of Cell Growth and Transparency (Supplement), 3R01E017963-06A1S1, (PI Vasilis Vasiliou), NIH/NEI, Total direct costs: $220,251.
* The Role of ALDH1B1 in Ethanol Metabolism and Colon Cancer;5 R01 AA021724-05 (PI Vasilis Vasiliou), NIH/NIAAA, Total direct costs: $1,328,578, 09/1/2014-08/31/2019.
* Summer Research Experiences in Environmental Health (SREEH), 1R25ES029052-01 (MPI Vasilis Vasiliou, Yong Zhu), NIH/NIEHS, Total direct costs: $494,213
* Fourth International Conference on Alcohol and Cancer, 1R13AA027725-01 (PI Vasilis Vasiliou), NIH/NIAAA, Total direct costs; $30,000.

**Pending**

* Translational Alcohol Research Program (TARP), 1T32AA026564-01A1, (MPI: Vasilis Vasiliou, Kelly Cosgrove), NIH/NIAAA, Total direct costs: $1,287,200.
* Metabolomics, Tissue-Imaging Mass Spectrometry, and Advanced Network-Analytics to Identify Biomarkers and Novel Pathways Involved in the Development of Alcoholic Liver Disease, 1R21AA027716-01 (PI Vasilis Vasiliou), NIH/NIAAA, Total direct costs: $275,000

**Past Support**

* Glutathione Monoesters to Counteract Ocular Chemical Injury (CounterACT) Exploratory/Development Projects in Translational Research, 1R21EY026776-01 (PI Vasilis Vasiliou), NIH/NEI, Total direct costs: $575,934, 9/30/15-9/29/18 (NCE).
* Mouse Models for Alcohol Metabolism and Tissue Injury; 5R24AA022057-06 (PI Vasilis Vasiliou), NIH/NIAAA, Total direct costs: $902,839, 02/01/2013-09/192018.
* 3rd International Alcohol and Cancer Conference. 1R13AA024046-01 (PI Vasilis Vasiliou), NIH/NIAAA, Total direct costs: $30,000, 04/01/2015-11/30/2017 (NCE).
* Role and Molecular Mechanisms Corneal Aldehyde Dehydrogenase, 7R01EY11490-16 (PI Vasilis Vasiliou), NIH/NEI, Total direct costs $1,801,728; 7/1/09-6/30/2016 (NCE).
* A Novel Aldehyde Dehydrogenase (ALDH16A1) in Gout; 5R21AR064137-02 (PI Vasilis Vasiliou), NIH/NIAMS, Total direct costs: $253,936; 09/16/2014-01/31/2017 (NCE).
* Mouse Models for Alcohol Metabolism and Tissue Injury, 3R24 AA022057-03S1 (PI Vasilis Vasiliou), NIH//NIAAA, Total direct costs $93,418, 8/1/13-1/31/17
* The role of GSH in cornea and lens development; 7R21EY021688-03, NIH/ NEI (PI Vasilis Vasiliou), 07/01/2012-08/31/2015.
* Biochemical, Structural and Polymorphic Characterization of Human ALDH1B1, 1F31AA020728-01, (NRSA fellowship for Brian Jackson; Role: **Mentor**) 07/01/2011-06/30/2015.
* Aldehyde Dehydrogenases as Targets to Treat Acute Myeloid Leukemia (PI Vasilis Vasiliou), Skaggs School of Pharmacy Colorado/University of Colorado. 7/1/11 – 6/30/2013.
* Alcohol and Cancer Conference. 1R13AA021659-01, NIAAA/NIH (PI Vasilis Vasiliou), 07/01/2012-08/30/2013
* Role of ALDH7A1 in Ethanol-Induced Oxidative Damage; 1 F31AA018248-01 (NRSA fellowship for Chad Brocker; **Role:** Mentor), ***Funded;*** $29,417 per year, $88,251 total; 09/30/2010 – 09/29/2013 (terminated due to graduation in May 2012).
* The role of mitochondrial aldehyde dehydrogenases in ethanol metabolism and toxicity, NIH/NIAAA, 1R21AA017754-01 Vasiliou (PI, Vasilis Vasiliou); ***Funded;*** Direct cost $275,000; 07/01/09-06/30/11.
* Aldehyde Dehydrogenase 3B1: Characterization and Role in Oxidative Stress 1 F31 AA016875-01 (Satori Marchitti Student, **Mentor** Vasilis Vasiliou), ***Funded;*** Direct Costs: $82,500; 1/1/07-12/31/09.
* Molecular Mechanisms and Role of the Corneal Aldehyde dehydrogenase NIH/NEI, R01EY11490-09S1 ((P.I. Vasilis Vasiliou, ***Funded;*** $78,950; 8/01/07 to 3/31/09.
* Molecular Mechanisms and Role of the Corneal Aldehyde dehydrogenase NIH/NEI, R01EY11490-06. (P.I. Vasilis Vasiliou), ***Funded;*** $1,250,000 (direct costs); 4/01/04 to 3/31/09.
* Role of Lipid Aldehydes in Ethanol-Induced Liver Injury, NIH/NIAAA, R01 AA09300. (Dennis R. Petersen P.I., Vasilis Vasiliou Co-PI), ***Funded;*** $1,400,000 (direct costs), 04/01/01-03/31/06.
* Genetic Models to Study Alcohol Toxicity. NIAAA R01 AA11885-01A1 (P.I. Vasilis Vasiliou), $867,203 (direct costs), 1/1/99-12/31/04.
* Role of Aldehyde Protein Adducts in CCl4-Induced Liver toxicity. NIEHS R01 ES09410-01A1, (Dennis R. Petersen P.I., Vasilis Vasiliou Co-PI), ***Funded;*** $1,250,854 (direct costs), 9/15/00-9/15/05.
* Role of CYP2E1 in Fetal Alcohol Syndrome, NIAAA, Predoctoral Fellowship for the student Susanne Williams, Mentor Vasilis Vasiliou, ***Approved;*** $45,000; 8/1/98 to 7/30/01.
* Molecular Mechanisms and Role of the Corneal Aldehyde dehydrogenase NIH/NEI, R29EY11490. (P.I. Vasilis Vasiliou) ***Funded;*** $349,835 (direct costs); 506,097 (total costs), 1/12/97 to 30/11/2002.
* Transgenic Mouse Models to Study the Role of Neurotensin Receptor in Ethanol Sensitivity, NIH/NIAA, Pilot project with the Alcohol Research Center. (Vasilis Vasiliou P.I.) ***Funded;*** $50,000, 12/1/99 to 11/30/02.
* Role of Lipid Aldehydes in Ethanol-Induced Liver Injury, NIH/NIAAA, R01 AA09300. (Dennis R. Petersen P.I., Vasilis Vasiliou Co-PI), ***Funded;*** $859,283 (direct costs) 1,283,085 (total costs), 04/01/97-03/31/01.
* Characterization of the ethanol metabolism pathways in Zebrafish. Department of Pharmaceutical Sciences Seed Grant. (Robert Tanguay & Vasilis Vasiliou) ***Funded;*** $10,000; 7/1/00 to 7/1/01.
* Pharmacogenetics of cyclophosphamide metabolism. Department of Pharmaceutical Sciences Seed Grant. (Mark Duncan, Daniel Gustafson, Peter Kazakoff, & Vasilis Vasiliou, Ph.D.) ***Funded;*** $10,000; 7/1/00 to 7/1/01
* Role of Neurotensin Receptor in Ethanol Sensitivity, Department of Pharmaceutical Sciences Seed Grant. (P.I. Vasilis Vasiliou) ***Funded;*** $10,000; 7/1/98 to 7/1/1999.
* Transcriptional Regulation of Genes Involved in Human Disease. Department of Pharmaceutical Seed Grant, (P.I., Vasilis Vasiliou) ***Funded;*** 5,000; 4/1/97 to 4/28/98.
* Transcriptional Activators of Oxidative Stress. Department of Pharmaceutical Sciences Seed Grant. (P.I. Vasilis Vasiliou) ***Funded;*** $10,000; 7/1/96 to 7/1/1997.
* Molecular Basis of Cyclophosphamide Resistance. Colorado Cancer Center Seed Grant. (P.I. Vasilis Vasiliou) ***Funded;*** $10,000; 9/8/96 to 8/30/97.

**PROFESSIONAL AND INSTITUTIONAL SERVICE**

**Editorial Boards:**

2005-present Cutaneous and Ocular Toxicology

2007-present The Ocular Surface

2013-present Expert Opinion on Drug Metabolism & Toxicology

**Executive Editor:**

2010-2016 Experimental Eye Research

**Editor-in-Chief:**

2008- [Human Genomics](http://www.humgenomics.com)

**Journal reviewer for:**Alcohol & Alcoholism, Alcoholism Clinical & Experimental Research, American Journal of Pathology, Archives of Biochemistry and Biophysics, Biochemical Pharmacology, Biochemical Biophysical Acta, British Journal of Nutrition, British Journal of Pharmacology; Cancer Letters, Cancer Chemotherapy and Pharmacology, Carcinogenesis, Cellular and Molecular Life Sciences, Chemical Research in Toxicology, Chemico-Biological Interactions, Comparative Biochemistry and Physiology, Clinical Chemistry and Laboratory Medicine, DNA Sequence, Digestive Diseases and Sciences, Drug Metabolism and Disposition, Experimental Eye Research, Genomics, Endocrine Reviews, European, Free Radicals in Biology and Medicine, Journal of Pharmacology, Journal of Human Genetics, Investigative Ophthalmology and Visual Sciences, International Journal of Cancer, International Journal of Biological Macromolecules

Life Sciences, Molecular Pharmacology, Journal of Biological Chemistry, Pharmacogenetics & Genomics.

**Reviewing for Granting Agencies**Greek Ministry of Research and Technology (2005; ad hoc).

NIH ZRG1 AED Study Section (2004-2005; ad hoc).

NIH ZRG1 AED Study Section (2005-2009; regular member).

NIH ZAA1 BB Study Section (2007; 2008; ad hoc).

NIH ZAA1 JJ (12) Study Section (2007; ad hoc).

NIH DPVS Study Section (March 2012; mail reviewer)

NIH CBSS Study Section (February 2012; ad hoc)

NIH ZRG1 MOSS-S (04) (March 2012; ad hoc)

NIH AA-1 Study Section (2009-2011; regular member)

NIH AA-1 Study Section (2011-2013; chair, and in 2017; ad hoc)

NIH DPVS Study Section (2013-2019; ad hoc)

NIH ZEY1 VSN study section (05) (August 2014 ad hoc)

NIH ZAA1 Study Section (2006-; meber and chair)

**Reviewer for Society of Toxicology, University of Colorado and Yale University**

**Specialist Advisor**

HUGO Gene Nomenclature Committee (<http://www.gene.ucl.ac.uk/nomenclature/advisors.html>)

**PUBLICATIONS**

1. Vasiliou V, Malamas M, Marselos M. The mechanism of alcohol intolerance produced by various therapeutic agents, **Acta Pharmacol et Toxicol** 58: 305-310, 1986. PMID: 2943133.
2. Vasiliou V, Marselos M. Tissue distribution of inducible aldehyde dehydrogenase activity in the rat after treatment with phenobarbital or methylcholanthrene. **Pharmacol & Toxicol** 64: 39-42, 1989. PMID: 2755909.
3. Vasiliou V, Marselos M. Changes in the inducibility of a hepatic aldehyde dehydrogenase by various effectors. **Arch Toxicol** 63: 221-225, 1989. PMID: 2764709.
4. Vasiliou V, Torronen R, Malamas M, Marselos M. Inducibility of liver cytosolic aldehyde dehydrogenase activity in various animal species. **Comp Biochem & Physiol** 94C: 671-675, 1989. PMID: 2576795.
5. Marselos M, Vasiliou V. Effects of various chemicals on the aldehyde dehydrogenase activity of the rat liver cytosol. **Chem Biol Interactions** 79: 79-89, 1991. PMID: 2060039.
6. Marselos M, Vasiliou V, Malamas M, Alikaridis F, Kefalas T. Effects of cannabis and tobacco on the enzymes of alcohol metabolism in the rat. **Rev Environm Health** 9: 31-37, 1991. PMID: 1957048.
7. Vasiliou V, Puga A, Nebert DW. Negative regulation of the murine cytosolic aldehyde dehydrogenase-3 (Aldh-3c) gene by functional CYP1A1 and CYP1A2 proteins. **Biochem Biophys Res Commun** 187: 413-419, 1992. PMID: 1520328.
8. Vasiliou V, Puga A, Nebert DW. Mouse class 3 aldehyde dehydrogenases: positive and negative regulation of gene expression. **Adv Exp Med Biol** 328: 131-139, 1993. PMID: 8493891.
9. Nebert DW, Puga A, Vasiliou V. Role of Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer and signal transduction. **Ann N Y Acad Sci** 658: 624-640, 1993. PMID: 8395783.
10. Vasiliou V, Reuter SF, Kozak CA, Nebert DW. Mouse Dioxin-inducible cytosolic aldehyde dehydrogenase: Ahd-4 cDNA sequence, genetic mapping, and differences in gene expression. **Pharmacogenetics** 3: 281-290, 1993. PMID: 8148869.
11. Liu R-M, Vasiliou V, Duh L, Puga A, Nebert DW, Sainsbury M, Shertzer HG. Regulation of [*Ah*] gene battery enzymes and glutathione levels by 5,10-dihydroindeno[1,2b]-indole in mouse hepatoma cell lines. **Carcinogenesis** 15: 2347-2352, 1994. PMID: 7955076.
12. Vasiliou V, Pappas P, Nebert DW, Marselos M. Lack of response of the rat liver class 3 cytosolic aldehyde dehydrogenase to toxic chemicals, glutathione depletion, and other forms of stress. **Biochem Pharmacol**48: 841-845, 1994. PMID: 8080457.
13. Vasiliou V, Theuer MJ, Puga A, Reuter SF, Nebert DW. Mouse dioxin-inducible NAD(P)H:menadione oxidoreductase: NMO1 cDNA sequence and genetic differences in gene expression. **Pharmacogenetics**4: 341-348, 1994.PMID: 7704040.
14. Vasiliou V, Reuter SF, Kozak CA, Nebert DW. Mouse Class 3 aldehyde dehydrogenases. **Adv Exp Med Biol** 372: 151-158, 1995. PMID: 7484373.
15. Pappas P, Vasiliou V, Karageorgou M, Stefanou P, Marselos M. Studies on the induction of the rat class 3 aldehyde dehydrogenase. **Adv Exp Med Biol** 372:143-150, 1995. PMID: 7484372.
16. Shertzer HG, Vasiliou V, Liu R-M, Tabor WM, Nebert DW. Enzyme induction by L-buthionine(S,R)-sulfoximine in cultured mouse hepatoma cells. **Chem Res Toxicol** 8: 431-436, 1995. PMID: 7578930.
17. Vasiliou V, Shertzer HG, Liu R-M, SainsburyM, Nebert DW. Response of the [*Ah*] battery genes to compounds that protect against menadione toxicity. **Biochem Pharmacol** 50: 1885-1891, 1995. PMID: 8615869.
18. Vasiliou V, Karageorgou M, Nebert DW, Marselos M. Ligands of four receptors in the nuclear steroid/thyroid superfamily inhibit induction of rat cytosolic aldehyde dehydrogenase-3 (ALDH3c) by 3-methylcholanthrene. **Biochem Pharmacol** 50: 2113-2217, 1995.PMID: 8849341.
19. Vasiliou V, Puga A, Ching-yi Chang, M. Tabor W, Nebert DW. Interaction between the Ah receptor and proteins binding to the AP-1-like electrophile responsive element (EpRE) during the murine phase II [*Ah*] battery gene expression. **Biochem Pharmacol** 50: 2057-2068, 1995. PMID: 8849333.
20. Vasiliou V, Weiner H, Marselos M, Nebert DW. Mammalian aldehyde dehydrogenase genes: clasification based on evolution, structure and regulation**. Eur J Drug Metab Pharmacokinet** 20: 53-64, 1995.
21. Marselos M, Karageorgou M, Stefanou P, Pappas P, Vasiliou V. Hormonal regulation of an inducible aldehyde dehydrogenase. **Eur J Drug Metab Pharmacokinet** 20:65-68, 1995.
22. Vasiliou V, Kozak CA, Lindahl R, Nebert DW. Mouse microsomal Class 3 aldehyde dehydrogenase: Ahd-3 cDNA sequence, chromosomal mapping, and dioxin inducibility. **DNA Cell Biol** 15: 235-245, 1996.PMID: 8634152
23. Marks-Hull H, Shiao, T-Y, Araki-Sasaki K, Traver R, Vasiliou V. Expression of ALDH3 and NMO1 in human corneal epithelial and breast adenocarcinoma cells. **Adv Exp Med & Biol** 414: 59-68, 1997. PMID: 9059607.
24. Vasiliou V, Reuter S, Shiao T-Y, Puga A, Nebert DW. Mouse-dioxin inducible Ahd4 gene: structure of the 5'flanking region and transcriptional regulation. **Adv Exp Med & Biol** 414: 37-46, 1997. PMID: 9059605.
25. Pappas P, Stephanou P, Vasiliou V, Karamanakos P, Marselos M. Ontogenesis and expression of ALDH activity in the skin and the eye of the rat. **Adv Exp Med & Biol** 414: 73-80, 1997. PMID: 9059609.
26. Vasiliou V. Aldehyde dehydrogenase genes. **Adv Exp Med & Biol** 414: 595-600, 1997. PMID: 9148643.
27. He X-X, Nebert DW, Vasiliou V, Zhu H, Shertzer H. Genetic differences in alcohol preference between inbred strains of mice. **Pharmacogenetics**7: 223-233, 1997. PMID: 9241662.
28. Vasiliou V, Reuter S, Nebert DW. Extrahepatic expression of NAD(P)H:menadione oxidoreductase (NMO1), UDP glucoronosyltransferase -1A6 (UGT1A6), microsomal aldehyde dehydrogenase (AHD3), and hepatic nuclear factor-1a (HNF-1a) mRNAs in *ch/ch* and *14CoS/14CoS* mice. **Biochem Biophys Res Commun** 233: 631-636, 1997. PMID: 9168903.
29. Pappas P, Stefanou P, Vasiliou V, Marselos M. Zoxazolamine-paralysis in two rat substrains: Differences in Hepatic drug metabolism. **Eur J Drug Metab Pharmacokinet** 23: 461-467, 1998. PMID: 10323328.
30. Pappas P, Stefanou P, Vasiliou V, Marselos M. Anti-inflammatory agents and inducibility of hepatic drug metabolism. **Eur J Drug Metab Pharmacokinet** 23:457-460, 1998. PMID: 10323327.
31. Ziegler T, Vasiliou V. Aldehyde dehydrogenase gene superfamily: The 1998 update. **Adv Exp Med & Biol** 463: 255-263, 1999. PMID: 10352694.
32. Vasiliou V, Shiao T. The lack of AHD4 induction by TCDD in corneal cells may involve tissue-specific regulatory proteins. **Adv Exp Med & Biol** 463: 181-188, 1999. PMID: 10352684.
33. Stefanou P, Pappas P, Vasiliou V, Marselos M. Prepubertal regulation of the rat dioxin-inducible aldehyde dehydrogenase (ALDH3c). **Adv Exp Med & Biol** 463: 143-150, 1999. PMID: 10352679.
34. Shiao T, Tran P, Siegel D, Lee J, Vasiliou V. Four amino acid changes are associated with the Aldh3a1 locus polymorphism in mice which may be responsible for corneal sensitivity to UV light. **Pharmacogenetics** 9: 145-153, 1999. PMID: 10376761.
35. Vasiliou V, Reuter SF, Williams S, Puga A, Nebert DW. Mouse cytosolic class 3 aldehyde dehydrogenase (*Aldh3a1*): Gene structure and regulation of constitutive and dioxin-inducible expression. **Pharmacogenetics** 9:569-80, 1999. PMID: 10591537.
36. Vasiliou V, Bairoch A, Tipton K, Nebert DW. Eukaryotic aldehyde dehydrogenase (*ALDH*) genes: Human polymorphisms, and recommended nomenclature based on divergent evolution and chromosomal mapping. **Pharmacogenetics**9: 421-434, 1999. PMID: 10780262.
37. Vasiliou V, Buetler T, Eaton DL, Nebert DW. Comparison of oxidative stress response parameters in newborn mouse liver versus SV40-transformed hepatocyte cell lines. **Biochem Pharmacol** 59:703-712, 2000. PMID: 10677587.
38. Vasiliou V, Lee J, Pappa A, Petersen DR. Involvement of p65 in the regulation of NF-kappaB in rat hepatic stellate cells during cirrhosis. **Biochem Biophys Res Commun** 273: 546-50, 2000. PMID: 10873642.
39. Vasiliou V, Pappa A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. **Pharmacology** 61:192-198, 2000. PMID: 10971205.
40. Reichard JF, Vasiliou V, Petersen DR. Characterization of 4-hydroxy-2-nonenal metabolism in stellate cell lines derived from normal and cirrhotic rat liver. **Biochim Biophys Acta** 1487: 222-232, 2000. PMID: 11018474.
41. Vasiliou V, Pappa A. Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. **Chem Biol Interactions** 129:1-19, 2000. PMID: 11154732.
42. Pappa A, Sophos NA, Vasiliou V. Corneal and stomach aldehyde dehydrogenases: from fish to mammals. **Chem Biol Interactions** 130-132(1-3): 181-191, 2001. PMID: 11306042.
43. Sophos NA, Pappa A, Ziegler T, Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2000 update. **Chem Biol Interactions** 130-132(1-3): 323-37, 2001. PMID: 11306055.
44. Pappas P, Stephanou P, Karamanakos P, Vasiliou V, Marselos M. Phenobarbital inducibility and differences in protein expression of an animal model. **Chem Biol Interactions** 130-132(1-3): 275-283, 2001. PMID: 11306051.
45. Vasiliou V, Sophos N. ALDH2. **Atlas Genet Cytogenet Oncol Haematol**. September 2001.   
    URL : <http://www.infobiogen.fr/services/chromcancer/Genes/ALDH2ID250.html>.
46. Manzer A, Pappa A, Estey T, Sladek N, Carpenter JF, Vasiliou V. Ultraviolet radiation decreases expression and induces aggregation of corneal ALDH3A1. **Chem Biol Interactions** 143-144: 5-22, 2003. PMID: 12604188.
47. Sophos NA, Vasiliou V. Aldehyde dehydrogenase gene superfamily: The 2002 update. **Chem Biol Interactions** 143-144: 45-53, 2003. PMID: 12604184.
48. PappaA, Chen C, Koutalos Y, TownsendAJ, Vasiliou V. ALDH3A1 protects human corneal epithelial cells from ultraviolet- and 4-hydroxy-2-nonenal-induced oxidative damage. **Free Radic Biol & Med 34:** 1178-1189**,** 2003. PMID: 12706498.
49. Manzer R, Qamar L, Estey T, Pappa A, Petersen DR, Vasiliou V. Molecular cloning and expression of the rabbit corneal ALDH1A1. **DNA Cell Biol 22:** 329-338, 2003. PMID: 12941160.
50. Vasiliou V, Qamar L, Pappa A, Sophos NA, Petersen DR. Involvement of the Electrophile Responsive Element (EPRE) and p53 in the Activation of Hepatic Stellate Cells as a Response to Electrophile Menadione. **Arch Biochem Biophys 413:** 164-171, 2003. PMID: 12729613.
51. Pappa A, Estey T, Manzer R, Brown D, Vasiliou V. Human aldehyde dehydrogenase 3A1 (ALDH3A1): Biochemical characterization and immunohistochemical localization in the cornea. **Biochem J 376**: 615-623, 2003. PMCID: PMC1223798.
52. DiFabio J, Ji Y, Vasiliou V, Thatcher GR, Bennett BM. Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. **Mol Pharmacol** **64:** 1109-1116, 2003. PMID: 14573760.
53. Vasiliou V, Pappa Agi, Estey T: Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. **Drug Metab** **Rev,** 36: 279-299, 2004. PMID: 15237855.
54. Mashek DG, Bornfeldt KE, Coleman RA, Berger J, Bernlohr DA, Black P, DiRusso CC, Farber SA, Guo W,Hashimoto N, Khodiyar V, Kuypers FA, Maltais LJ, Nebert DW, Renieri A, Schaffer JE, Stahl A, Watkins PA, Vasiliou V, Yamamoto TT. Revised nomenclature for the mammalian long chain Acyl-CoA synthetase (ACS) gene family. **J. Lipid Res,** 45: 1958-61, 2004. PMID: 15292367.
55. Nebert DW, Sophos NA, Vasiliou V, Nelson DR. Cyclophilin nomenclature problems, or, “a visit from the sequence police”. **Human Genomics 1: 381-388,** 2004. PMCID: PMC3525097.
56. Nebert DW, Vasiliou V: Analysis of the glutathione S-transferase (GST) gene family. **Human Genomics,** 1: 460-464, 2004. PMCID: PMC3500200.
57. Kenney M. C, Chwa M, Atilano S, Tran A, Carballo M, Saghizadeh M, Vasiliou V, Adachi W, Brown DJ. Increased Catalase and Cathepsin V/L2 but Decreased TIMP-1 in Keratoconus Corneas: Evidence that Oxidative Stress Plays a Role in This Disorder. **Invest. Ophthalmol Vis Sci,**46: 823-832, 2005. PMID: 15728537.
58. Gurwitz D, Lunshof JE, Dedoussis G, Flordellis CS, Fuhr U, Kirchheiner J, Licinio J, Llerena A, Manolopoulos VG, Sheffield LJ, Siest G, Torricelli F, Vasiliou V**,** Wong S. Pharmacogenomics Education: ISP Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. **Pharmacogenomics J,** 5: 221-225**, 2005.** PMID: 15852053.
59. Lassen N, Estey T, Tanguay R, Pappa A, Reimer MJ, Vasiliou V. Molecular cloning, baculovirus expression and tissue distribution of the zebrafish ALDH2. **Drug Metab Dispos,** 33: 649-56, 2005. PMID: 15703303.
60. Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase family. **Human Genomics**, 2: 138-143, 2005. PMCID: PMC3255259.
61. Pappa A, Brown D, Koutalos Y, Degregori J, White C, Vasiliou V. Human aldehyde dehydrogenase 3A1 (ALDH3A1) inhibits proliferation and promotes survival of human corneal epithelial cells. **J Biol Chem,** 280: 27998-28006, 2005. PMID: 15905174.
62. Black W, Vasiliou V. Ocular metabolism and disposition of 4-hydroxl-2-nonenal. **Cutaneous and Ocular Toxicology**, 24:155-176, 2005.
63. Vasiliou V, Ziegler TL, Bludeau P, Petersen DR, Gonzalez FJ, Deitrich RA. CYP2E1 and catalase influence ethanol sensitivity in the central nervous system. **Pharmacogenet Genomics** 16:51-8, 2006. PMID: 16344722.
64. Panayiotidis MI, Stabler SP, Ahmad A, Pappa A, Legros LH, Hernandez D, Schneider K, Allen RH, Vasiliou V, McCord JM, Kotb M, White CW. Activation of a novel isoform of methionine adenosyltransferase 2A and increased S-adenosylmethionine turnover in lung epithelial cells exposed to hyperoxia. **Free Radic Biol & Med,** 40:348-58, 2006. PMID: 16413417.
65. Vasiliou V, Ross D, Nebert DW. Update of the NAD(P)H:quinone oxidoreductase (*NQO*) gene family. **Human Genomics** 2:329-335, 2006. PMCID: PMC3500182.
66. MuzioG, Trombetta A, Maggiora M, Martinasso G, Vasiliou V, Lassen N, Canuto RA. Arachidonic acid suppresses growth of human lung tumor A549 cells through down regulation of ALDH3A1 expression. **Free Radic Biol & Med,** 40:1929-38, 2006. PMID: 16716894.
67. Zimatkin SM, Pronko PS, Vasiliou V, Gonzalez FJ, Deitrich RA. Enzymatic mechanisms of ethanol oxidation in the brain of rats and mice. **Alc Clin Exp Res,** 30: 1500-1505, 2006. PMID: 16930212.
68. Horwitz J, Ding L, Vasiliou V, Cantore M, Piatigorsky J. Scallop lens -crystallin (ALDH1A9): A novel tetrameric aldehyde dehydrogenase. **Biochem Biophys Res Commun,** 348: 1302-1309, 2006. PMID: 16919242.
69. Bhave SV, Hoffman PL, Lassen N, Vasiliou V, Deitrich RA, Tabakoff B. Gene array profiles of alcohol and aldehyde metabolizing enzymes in brain of mice which differ in their response to ethanol. **Alc Clin Exp Res,** 10: 1-11, 2006. PMID: 17010133.
70. Lassen N, Pappa A, Black WJ, Jester JV, Day B, Min E, Vasiliou V. Antioxidant function of corneal ALDH3A1in cultured stromal fibroblasts. **Free Radic Biol & Med,** 41:1459-69, 2006. PMID: 17023273.
71. Estey T, Piatigorsky J, Lassen N, Vasiliou V. ALDH3A1: a corneal crystallin with diverse functions. **Exp. Eye Res**, 84: 3-12, 2007. PMID: 16797007.
72. Estey T, Weston PA, Cantore M, Carpenter J, Petrash JM, Vasiliou V. Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1, **J Biol Chem**. 282:4382-92, 2007. PMID: 17158879.
73. Marchitti SA, Deitrich RA, Vasiliou V. Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde (DOPAL) and 3,4-Dihydroxyphenylglycolaldehyde (DOPEGAL): The Role of Aldehyde Dehydrogenase, **Pharmacol Reviews,** 59: 125-50, 2007. PMID 17379813.
74. Marchitti SA, Orlicky DJ, Vasiliou V. Expression and initial characterization of human ALDH3B1. **Biochem Biophys Res Commun,** 356: 792-798, 2007. PMCID: PMC1899873.
75. Jia S, Omelchenko S, Garland D, Vasiliou V, Kanungo J, Spencer M, Koonin E, Piatigorsky, J. Duplicated gelsolin-family genes in zebrafish: a novel scinderin-like gene (*scinla*) encodes the major corneal crystallin. **FASEB J, 21**: 3318-28, 2007.PMID: 17548429.
76. Lassen N, Bateman BJ,Estey T, Kuszak JR,Nees D, Piatigorsky J, Duester G, Day B, Huang J, Hines L, Vasiliou V. Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in *Aldh1a1-/-/Aldh3a1-/-* knockout mice, **J Biol Chem,** 282: 25668-76, 2007.PMCID: PMC2253645.
77. Vasiliou V, Gonzalez FJ. The role of CYP1B1 in glaucoma. **Ann Rev Pharmacol Toxicol,** 48:333-358, 2008. PMID: 17914928.
78. Lassen N, Black WJ, Estey T, Vasiliou V: The Role of Corneal Crystallins in the Cellular Defense Mechanisms Against Oxidative Stress. **Semin Cell Dev Biol,** 19:100-12, 2008. PMID: 18077195.
79. Marchitti SA, Brocker C, Stagkos D, Vasiliou V. Non-P450 alcohol and aldehyde metabolizing enzymes. ***Expert* Opinion on Drug Metab & Toxicol*,***  4: 697-720, 2008. PMCID: PMC2658643.
80. D’Amelio S, Lassen N, Vasiliou V, Bateman BJ. Duane Retraction Syndrome, Nystagmus, Retinal Pigment Epitheliopathy and Epiretinal Membrane with Micro- and Pachygyria, Developmental Delay, Hearing Loss and Craniopharyngioma. **Ophtmalmic Genetics**, 30:7-12, 2009. PMID: 19172504.
81. Stagos D, Zhou H, Ross D, Piatigorsky J, Vasiliou V. 4-Hydroxynonenal inhibits angiogenesis *in vitro* and up-regulates Chondromodulin-I. **Biochem Biophys Res Commun,** 379: 654-58, 2009. PMCID: PMC2757412.
82. Xiao T, Shoeb M, Zhang M, Ramana KV, Srivastava SK, Vasiliou V, Ansari NA. Molecular cloning and oxidative modification of human lens ALDH1A1: Implication in impaired detoxification of lipid aldehydes. **J Toxicol Environ Health A.** 72: 577-84, 2009. PMID: 19296407.
83. Vasiliou V, Vasiliou K, Nebert DW, Human ATP-binding cassette (ABC) transporter family. **Hum. Genomics,** 3:281-90, 2009. PMCID: PMC2752038.
84. Chen Y, Johansson E, Fan Y, Shertzer HG, Vasiliou V, Nebert DW, Dalton TP. Early onset senescence occurs when fibroblasts lack glutamate cysteine ligase modifier subunit. **Free Radic Biol Med.** 47:410-8, 2009. PMCID: PMC2773044.
85. Chen Y, Mehta G, Vasiliou V. Antioxidant Defenses in Ocular Surface. **Ocul Surf,** 7: 176-185, 2009. PMCID: PMC4104792.
86. Black W, Stagkos D, Marchitti SA, Nebert DW, Tipton K, Bairoch A, Vasiliou V. Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature. **Pharmacogenet Genomics.** 19: 893-902, 2009. PMCID: PMC3356695.
87. Brocker CN, Vasiliou V, Nebert DW, Evolutionary Divergence and Functions of the *ADAM* and *ADAMTS* Gene Families. **Hum. Genomics,** 4:43-55, 2009. PMCID: PMC3500187.
88. Endo J, Sano M, Katayama T, Hishiki T, Shinmura K, Morizane S, Matsuhashi T, Katsumata Y, Zhang Y, Ito H, Nagahata Y, Marchitti S, Nishimaki K, Wolf AM, Nakanishi H, Hattori F, Vasiliou V, Adachi T, Ohsawa I, Taguchi R, Hirabayashi Y, Ohta S, Suematsu M, Ogawa S, Fukuda K. Metabolic Remodeling Induced by Mitochondrial Aldehyde Stress Stimulates Tolerance to Oxidative Stress in the Heart. **Circ Res.** 105: 1118-27, 2009. PMID: 19815821.
89. Black W, Vasiliou V. The Aldehyde Dehydrogenase Gene Superfamily Resource Center. **Hum. Genomics,** 4: 136-142, 2009. PMCID: PMC3525204.
90. Stagos D, Chen Y, Cantore M, Jester JV, Vasiliou V, Corneal Aldehyde Dehydogenases: Multiple Functions and Novel Nuclear Localization. **Brain Res Bull.** 81: 211-218, 2010, PMCID: PMC3025408.
91. Jackson BC, Nebert DW, Vasiliou V. Update of human and mouse matrix metalloproteinase families. **Hum. Genomics,** 4:194-201, 2010,PMCID: PMC3525976.
92. Brocker C, Lassen N, Estey T, Pappa A, Cantore M, Orlova VV, Chavakis T, Kavanagh KL, Oppermann U, Vasiliou V. Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress, **J. Biol Chem,** 285:18452-63, 2010, PMCID: PMC2881771.
93. Marchitti SA, Orlicky DJ, Vasiliou V, Aldehyde Dehydrogenase 3B1 (ALDH3B1): Immunohistochemical Tissue Distribution and Cellular-Specific Localization in Normal and Cancerous Human Tissues.  **J Histochem Cytochem,** 58:765-83, 2010, PMCID: PMC2924794.
94. Jackson BC, Carpenter C, Nebert DW, Vasiliou V. [Update of human and mouse forkhead box (FOX) gene families.](http://www.ncbi.nlm.nih.gov/pubmed/20650821) **Hum Genomics**, 4: 345-52, 2010, PMCID: PMC3500164.
95. Stagos D, Chen Y, Brocker, C, Donald E, Jackson BC, Orlicky D, Thompson D, Vasiliou V, Aldehyde dehydrogenase 1B1 (ALDH1B1): Molecular cloning and characterization of a novel mitochondrial acetaldehyde metabolizing enzyme, **Drug Metab Dispos,** 38:1679-87, 2010, PMCID: PMC2957164.
96. Brocker C, Carpenter C, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human acyl-CoA thioesterase gene (*ACOT*) family. **Hum Genomics**, 4:411-20, 2010, PMCID: PMC3525216.
97. Marchitti SA, Brocker C, Orlicky D, Vasiliou V.Molecular characterization, expression analysis and the role of ALDH3B1 in cellular defense against oxidative stress, **Free Radic Biol Med,** 49:1432-43, 2010, PMCID: PMC3457645.
98. Scharer G, Brocker C, Vasiliou V, Creadon-Swindell G, Gallagher RC, Spector E, Van Hove JLK. The genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy due to mutations in ALDH7A1. **J Inherit Metab Dis.** 33(5): 571-8, 2010, PMCID: PMC3112356.
99. Chen Y, Johansson E, Yang Y, Miller ML, Shen D, Stringer KF, Shertzer HG, Nebert DW, Vasiliou V, and Dalton TP. Oral *N*-acetylcysteine rescues lethality of hepatocyte-specific *Gclc* knockout mice providing a model for hepatic cirrhosis. **J Hepatol**. 53:1085-94, 2010, PMCID: PMC2970663.
100. Estey T, Chen Y, Carpenter J, Vasiliou V. Structural and functional modifications of corneal crystallin ALDH3A1 by UVB light. **PloSONE** 5:e15218, 2010, PMCID: PMC3006428.
101. Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. [Evolutionary divergence and functions of the human interleukin (IL) gene family.](http://www.ncbi.nlm.nih.gov/pubmed/21106488) **Hum Genomics**. 5:30-55, 2010, PMCID: PMC3390169.
102. Chen Y, Orlicky DJ, Matsumoto A, SinghS, ThompsonDC, Vasiliou V. Aldehyde dehydrogenase 1B1 (ALDH1B1) Is a Potential Biomarker for Human Colon Cancer, **Biochem Biophys Res Commun,** 405(2): 173-9, 2011, PMCID: PMC3112362.
103. Oraldi M, Saracino S, Maggiora M, Chiaravalloti A, Buemi C, Martinasso G, Paiuzzi E, Thompson DC, Vasiliou V,Canuto RA. Importance of Inverse Correlation Between ALDH3A1 and PPARγ in Tumour Cells and Tissue Regeneration. **Chemico-Biol Interactions,** 191: 171-176, 2011,PMID: 21251908.
104. Brocker C, Cantore M, FailliP, Vasiliou V. Aldehyde dehydrogenase 7A1 (ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity. **Chemico-Biol Interactions*,*** 191: 269-277, 2011, PMCID: PMC3387551.
105. Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, Vasiliou V. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. **Hum Genomics** 5:283-303, 2011, PMCID: PMC3392178.
106. Marchitti S, Chen Y, Thompson DC, Vasiliou V. Ultraviolet radiation: cellular antioxidant response and the role of ocular aldehyde dehydrogenase enzymes. **Contact Eye Lens**, 37: 206-213, 2011, PMCID: PMC3356694.
107. Khanna M, Chen CH, Kimble-Hill A, Parajuli B, Perez-Miller S, Baskaran S, Kim J, Dria K, Vasiliou V, Rosen DM, and Hurley TD. Discovery of a novel class of suicide inhibitor for aldehyde dehydrogenases. **J. Biol Chem**, 286: 43486–4349, 2011, PMCID: PMC3234859.
108. Jackson BJ, David C. Thompson DC, Wright MW, McAndrews M, Bernard A, Nebert DW, Vasiliou V.  Update of the human secretoglobin (SCGB) gene superfamily and an example of ‘evolutionary bloom of androgen-binding protein genes within the mouse Scgb gene superfamily. **Hum Genomics**, 5: 691-702, 2011, PMCID: PMC3251818.
109. Chen Y, Thompson DC, Vasiliou V. Focus on molecules: ALDH1A1 from lens and corneal crystallin to stem cell marker. **Exp. Eye Res**, 102:105-6, 2012, PMCID: PMC3423494.
110. Monte AA, Heard KJ, Vasiliou, V. Prediction of drug response and toxicity in clinical practice.  **J Med Toxicol.** 8: 43-51, 2012, PMCID: PMC3550218.
111. Gasparetto M, Sekulovic S, Brocker C, Tang P, Zakaryan A, Xiang P, Kuchenbauer F, Wenn M, Katayoon K, Witty MF, Rosten P, Chen Y, Imren S, Duester G, Thompson DC, Humphries RK, Vasiliou V, Smith C. Aldehyde dehydrogenases are regulators of hematopoietic stem cell numbers and B-cell development. **Exp. Hematol**, 40:318-329**,** 2012,PMID: 22198153.
112. Zhang J-X, Li D-Q, He AR, Motwani M, Vasiliou V, Eswaran J, Mishra L, Kumar R. Synergistic Inhibition of Hepatocellular Carcinoma Growth by Cotargeting Chromatin Modifying Enzymes and Poly (ADP-ribose) Polymerases. **Hepatology**, 55:1840-51, 2012 PMCID: PMC3470855.
113. Jester JV, Nien C, Flynn K, Wahlert A, Brown D, Pappa A, Vasiliou V. Myofibroblast Differentiation Modulates Keratocyte Crystallin Protein Expression, Concentration and Cellular Light Scattering. **Invest Ophthalmol Vis Sci,** 53:770-8,2012**,** PMCID: PMC3317419.
114. Black WJ, Chen Y, Matsamuto A, Lassen N, Pappa  A, Thompson DC, Vasiliou, V. Molecular Mechanisms of ALDH3A1-mediated Cellular Protection Against 4-hydroxy-2-nonenal.**Free Radic Biol Med**, 52:1937-44, 2012, PMCID: PMC3457646.
115. Zhang Y, Mao L, Wang H, Brocker C, Xiangjing Yin Xn, Vasiliou V, Fei Z, Xiping Wan X. Genome-wide identification and analysis of grape aldehyde dehydrogenase (ALDH) gene superfamily. **Plos One***, 7:e32153, 2012*, PMCID: PMC3280228.
116. Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, Petersen DR, Dietrich RA, Hurley TD, Vasiliou V***.*** Aldehyde Dehydrogenase Inhibitors: A Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity and Clinical Application, **Pharmacol Rev**, 64:520-39, 2012, PMCID: PMC3400832.
117. Jester JV, Nien C-J, Vasiliou V, Brown DJ. Quiescent keratocytes fail to repair MMC induced DNA damage leading to the long-term inhibition of myofibroblast differentiation and wound healing. **Mol Vis**, 18:1828-39, 2012, PMCID: PMC3398499.
118. Gasparetto M, Sekulovic S, Zakaryan A, Imren S, Humphries SK, Vasiliou V, Smith C. Varying levels of aldehyde dehydrogenase activity in murine marrow hematopoietic stem cells is associated with engraftment and cell cycle status. **Exp Hematol,** 40:857-66, 2012, PMID: 22683567.
119. Brocker C, Thompson DC, Vasiliou V. The Role of Hyperosmotic Stress in Inflammation and Disease. **Biomol Concepts**, 3: 345–364, 2012, PMCID: PMC3438915.
120. Luo Y, Dallaglio K, ChenY, Robinson WA, Robinson SE, McCarter MD, Gonzalez R, Norris DA, Roop DR, Vasiliou V, Fujita M. ALDH is a marker of human melanoma stem cells and a potential therapeutic target. **Stem Cells,** 30:2100-13, 2012, PMCID: PMC3448863.
121. Saw Y-T, Yang J, Ng S-K, Liu S, Singh S, Singh M, Welch WR, Tsuda H, Fong W-P, Thompson DC, Vasiliou V, Berkowitz RS, Ng S-W. Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. **BMC Cancer** 12:329, 2012, PMCID: PMC3458927.
122. Brocker C, Vasiliou M, Carpenter S, Carpenter C, Zhang Y, Wang X, Kotchoni SO, Wood AJ, Kirch HH, Kopency D, Nebert DW, Vasiliou V. Aldehyde dehydrogenase (ALDH) superfamily in plants: Gene nomenclature and comparative genomics, ***Planta,*** 237:189-210, PMCID: PMC3536936.
123. Chen Y, Thompson DC, Koppaka V, Jester JV, Ocular aldehyde dehydrogenases: protection against ultraviolet damage and maintenance of transparency for vision, **Prog Retin Eye Res,** 33:28-39,2013, PMCID: PMC3570594.
124. Monte AA, Vasiliou V, Heard KJ. Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice**,** ***J******Pharmacogenomics Pharmacoproteomics****, 2012, S5,* PMCID: PMC3526192**.**
125. Ioannou M, Serafimidis I, Sussel L, Arnes L, Singh S, Vasiliou V, Gavalas A. ALDH1B1 is a potential stem/progenitor marker for multiple pancreas progenitor pools, **Developmental Biol,** 374:153-63, 2013,PMCID: PMC3580293.
126. Vasiliou V, Thompson DC, Smith C, Fujita M, Chen Y. Aldehyde dehydrogenases: From eye crystallins to metabolic disease and stem cells. ***Chem Biol Interact***, 202:2-10, 2013,PMCID: PMC4128326.
127. Singh S, Brocker C, Koppaka V, Chen Y, Jackson B, Matsumoto A, Thompson DC, Vasiliou V. Aldehyde Dehydrogenases in Cellular Responses to Oxidative/electrophilic Stress,**Free Radic Biol Med, 56:89-101,** 2013, PMCID: PMC3631350.
128. Bchini R, Vasiliou V, Guy Branlant G, Talfournier F, Rahuel-Clermont S. Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition.**Chem Biol Interact.** 202:78-84, 2013, PMCID: PMC3602353.
129. Heit C, Dong H, Chen Y, Thompson DC, Deitrich RA, Vasiliou V. The Role of CYP2E1 in alcohol metabolism and sensitivity in the central nervous system. In “*Cytochrome P450 2E1: Its Role in Disease and Drug Metabolism*” **Subcell Biochem**. 67:235-47, 2013, PMCID: PMC4314297.
130. Jackson BC, Holmes RS, Backos DS, Reigan P, Vasiliou V. Comparative genomics and molecular modeling of ALDH2 and ALDH1B1: Evidence for early vertebrate origin of ALDH1B1 from the ALDH2 gene and protein heterodimerization. **Chem Biol Interact**, 202:11-21, 2013, PMCID: PMC3687035.
131. Vasiliou V, Sandoval M, Backos DS, Jackson BC, Chen Y, Reigan P, Lanaspa MA, Johnson RJ, Koppaka V, Thompson DC. ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1. **Chem Biol Interact,** 202: 22-31, 2013, PMCID: PMC3746320.
132. Dong, H; Shertzer HG, Genter MB, PhD; Gonzalez FJ, Vasiliou V, Jefcoate C, Nebert DW, Mitochondrial targeting of mouse NQO1 and CYP1B1 proteins, **Biochem Biophys Res Commun**, 435(4):727-32, 2013, PMCID: PMC3735136.
133. LaGier AL, Gordon GM, Katzman LR, Vasiliou V, Fini ME, Mechanisms for PDGF, a serum cytokine, stimulating loss of corneal keratocyte crystallins, **Cornea,** 32:1269-1275, 2013*,* PMCID: PMC3874843.
134. Patrinos GP, Baker DJ, Al-Mulla F, Vasiliou V, Cooper DN. Genetic tests obtainable through pharmacies: the good, the bad and the ugly. **Hum Genomics**, 7:17. doi: 10.1186/1479-7364-7-17, PMCID: PMC3711749.
135. Chen Y, Dong H, Thompson DC, Shertzer HG, Nebert DW, Vasiliou V. Glutathione defense mechanism in liver injury: insights from animal models. **Food Chem Toxicol,** 60:38-44, 2013, PMCID: PMC3801188.
136. Heit C, Jackson BC, McAndrews M, Wright MW, Thompson DC, Silverman GA, Nebert DW, Vasiliou V. Update of the human and mouse SERPIN gene superfamily. **Hum Genomics**. 7:22, 2013, PMCID: PMC388077.
137. Jang JH, Bruse S, Liu Y, Duffy V, Zhang C, Lin Y, Randell SH, Thompson DC, Vasiliou V, Tesfaigzi Y, Nyunoya T. Aldehyde dehydrogenase 3A1 protects airway epithelial cells from cigarette smoke-induced DNA damage and cytotoxicity. **Free Radic Biol Med,** 68:80-86, 2014, PMCID: PMC3941192.
138. Kwon H-J, Won Y-S, Park O, Duryee MJ, Thielle GE, Matsumoto A, Sigh S, KawamotoT, Abdelmegeed MA, Song BJ, Vasiliou V, Thiele GM, Gao B. Aldehyde dehydrogenase 2 deficiency ameliorates fatty liver but exacerbates liver inflammation and fibrosis in mice. **Hepatology**, 60(1):146-57, 2014 PMCID: PMC4077916.
139. Smith C, Gasparetto M, Humphries K, Pollyea DA, Vasiliou V, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. **Ann N Y Acad Sci.** 1310: 58-68, 2014, PMID: 24641679.
140. Matsumoto A, Vasiliou V, Kawamoto T; Tanaka K; Ichiba M. Ethanol reduces lifespan, body weight, and serum alanine aminotransferase level of Aldehyde dehydrogenase 2 knockout mouse. **Alcohol Clin Exp Res**, 38:1883-93, 2014, PMID: 24930774.
141. Babcock HE, Dutta S, Alur RP, Brocker C, Vasiliou V, Vitale S, Brooks BP. Aldh7a1 regulates eye and limb development in zebrafish. **PLoS One,** 9(7): e101782, 2014. PMCID: PMC4086958.
142. Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. **Acad Emerg Med**, 8:879-885, 2014, PMCID: PMC4150819.
143. Monte AA, Heard KJ, Hoppe JA, Vasiliou V, Gonzalez FJ. The accuracy of self-reported drug ingestion histories in emergency department patients. **J Clin Pharmacol**, 55(1): 33-8, 2014, PMCID: PMC4276443
144. MonteAA, Brocker C, Nebert DW, GonzalezFJ, Thompson DC, Vasiliou V, Improved drug therapy: triangulating phenomics with genomics and metabolomics. **Hum Genomics**, 8:16, 2014, PMCID: PMC4445687.
145. SmithCC, GasparettoM, Craig Jordan C, PollyeaDA, VasiliouV. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. **Adv Exp Med Biol**, 815:349-59, 2015, PMID: 25427917.
146. Singh S, Arcaroli J, Thompson DC, Messersmith W, Vasiliou V. Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and pancreatic cancers. **Adv Exp Med Biol,** 815:281-94, 2015, PMCID: PMC4347404.
147. Heit C, Dong H, Chen Y, Shah Y, Thompson DC, Vasiliou V, Transgenic mouse models for alcohol metabolism, toxicity and cancer. **Adv Exp Med Biol**, 815:375-87, 2015, PMCID: PMC4323349.
148. Jackson BC, Reigan P, Thompson DC, Vasiliou V. Human ALDH1B1 polymorphisms may affect the metabolism of nitroglycerin and all-trans retinaldehyde - in vitro studies and computational modeling. **Pharm Res, 32:1648-62** PMID: 25413692: PMC4382438
149. Singh S, Arcaroli J, Chen Y, David C. Thompson DC, Messersmith W, Antonio Jimeno A and Vasiliou V. ALDH1B1 is crucial for colon tumorigenesis by modulating Wnt/β-catenin, notch and PI3K/Akt signaling pathways. **PLoS One** 10(5):e0121648**,** PMCID: PMC4423958.
150. Singh S, Chen Y, Matsumoto A, Orlicky DJ, Dong H, Thompson DC, Vasiliou V. ALDH1B1 links alcohol consumption and diabetes. **Biochem Biophys Res Commun,** 463:768-73, 2015, PMID: 26086111; PMCID4517591
151. Yang S-M, Yasgar A, Miller B, Lal M, Brimacombe K, Hu X, Sun H, Wang A, Xu X, Nguyen K, Oppermann U, Ferrer M, Vasiliou V, Simeonov A, Jadhav A, David J. Maloney DJ. Discovery of NCT-501. A Potent and Selectice Theophylline-Based inhibitor of Aldehyde Dehydrogenase 1A1 (ALDG1A1) **J Med Chem,**58: 5967-78, 2015 PMID: 26207746. PMC5185321
152. JacksonBC, ThompsonDC, CharkoftakiG, Vasiliou V. Dead enzymes in the aldehyde dehydrogenase gene family: Role in drug metabolism and toxicology. **Expert Opin Drug Metab Toxicol,** 11: 1839-47, 2015, PMID: 26558415. PMC4937717

158. DongH, NebertDW, Bruford EB, ThompsonDC, Joenje H, Vasiliou V. [Update of the human and mouse Fanconi anemia genes](http://www.ncbi.nlm.nih.gov/pubmed/24172014). **Hum Genomics*,*** 9: 32, 2015, PMCID: PMC4657327.

1. Singh S, Arcaroli JJ,OrlickyDJ, Chen Y, Wells A. Messersmith WA, Stacey Bagby S, Purkey A, Quackenbush KS, Thompson DC, Vasilis Vasiliou V. ALDH1B1 as a modulator of pancreas adenocarcinoma, **Pancreas,**45:117-22, 2016, PMID: 26566217: PMC5175203
2. Koppaka V, Ying Chen, Mehta G, Lassen N, Orlicky DJ, Thompson DC, Vasiliou V. ALDH3A1 plays a functional role in maintenance of corneal epithelial homeostasis. **PLoS One**, 11(1): e0146433. 2016, PMID: 26751691, PMCID: PMC4708999.
3. Matsumoto A, Thompson D, Chen Y, Vasiliou V, Kawamoto T, Ichiba M. Heme oxygenase 1 protects ethanol-administered liver tissue in *Aldh2* knockout mice. ***Alcohol***, 52:49-54. 2016. PMID: 27139237.
4. Heit C, Eriksson P, Thompson DC, Charkoftaki G, Fritz K, Vasiliou V. Quantification of neural ethanol and acetaldehyde using headspace GCMS*.* **Alcohol Clin Exp Res,** 40:1825-31, 2016, PMID: 27501276. PMC5008984
5. Chen Y, Singh S, Matsumoto A, Manna SK, Abdelmegeed MA, Golla S, Murphy RC, Dong H, Song BJ, Gonzalez FJ, Thompson DC, Vasiliou V. Redox activation of LKB1-AMPK pathway protects against alcohol-induced steatosis. **Sci Rep**,6:29743, 2016,PMCID: PMC4940737.
6. DongH, NebertDW, Bruford EB, ThompsonDC, Joenje H, Vasiliou V. Letter to the editor for "Update of the human and mouse Fanconi anemia genes". **Hum Genomics*,*** 10: 25, 2016, PMCID: PMC4932714.
7. Keysar SB, Le NP, Miller B,Kim J, Eagles JR, Cera Nieto C, Tang B, Glogowska MJ JJ, Jackson BC, Anderson RT, Padilla-Just N, Warnock E, Reisinger J, Arcaroli JJ, Messersmith WA, Wakefield LM, Tan A-C, Serracino H, Vasiliou V, Roop DR, Wang X-J, and Jimeno A. Regulation of head and neck squamous cancer stem cells by PI3K and SOX2. **J Natl Cancer Inst.** 109(1), pii: djw189, 2016. PMID:27634934; PMC5025278.
8. Matsumoto A; Thompson DC, Chen Y, Kitagawa K, Vasiliou, V. Roles of defective ALDH2 polymorphism on liver protection and cancer development. **Environ Health Prev Med.**  21:395-402, 2016, PMID: 27714678, PMC5112207.
9. Heit C, Marshall S, Singh S, Yu X, CharkoftakiG, Zhao H, Orlicky D, Fritz KS, Vasiliou V. Catalase deletion promotes pre-diabetic phenotype in mice. **Free Radic Biol Med** 103:48-56, 2017**,** PMID:27939935.
10. Berríos-Cárcamo P, Quintanilla M, Herrera-Marschitz M, Vasiliou V, Zapata-Torres G, Rivera-Meza M. Racemic Salsolinol and its Enantiomers Act as Agonists of the u-Opioid Receptor by Activating the Gi Protein-Adenylate Cyclase Pathway. **Front Behav Neurosci**, 10:253, 2017, PMCID: PMC5253357, PMID: 28167903.
11. MakTW, Grusdat M, Duncan GS, Dostert C, NonnenmacherY, Cox M, BinsfeldC, Hao Z, BrüstleA, ItsumiM, Jager C, ChenY, Pinkenburg O, Camara B, OllertM, Bindslev-JensenC, VasiliouV, GorriniC, Lang, PA, Lohoff M, HarrisIS, HillerK, Brenner D. Glutathione primes T cell metabolism for inflammation. **Immunity,** 46:675-689, 2017**,** PMID:28423341.
12. YasgarA, Titus SA, Wang Y, Danchik C, Yang SM, Vasiliou V, Jadhav A, Malone DJ, Simeonov A, Martinez NJ. A high-content assay enables the automated screening and identification of small molecules with specific ALDH1A1-inhibitory activity. **PLoS One**, 12:e0170937, 2017, PMID:28129349, PMC5271370.
13. Chen Y, Jester J, Anderson D, Marcitti S, Schey KL, Thompson DC, Vasiliou V. Corneal haze phenotype in *Aldh3a1*-null mice: In vivo confocal microscopy and tissue imaging mass spectrometry. **Chem Biol Interact,** 276:9-14, 2017, PMID:28038895. [Epub ahead of print].
14. Charkoftaki G, Chen Y, Han M, Sandoval M, Yu X, Zhao H, Orlicky DJ, Thompson DC, Vasiliou V. Transcriptomic analysis and plasma metabolomics in Aldh16a1-null mice reveals a potential role of ALDH16A1 in renal function. **Chem Biol Interact,** 276:15-22, 2017, PMID:28254523.
15. Rattray, J.W.R., Charkoftaki, G, Rattray, Z., Hanes, J.E., Vasiliou, V., Johnson, C.H. Environmental Influences in the Etiology of Colorectal Cancer: The Premise of Metabolomics, **Curr Pharmacol Rep,** Online 7 April, 2017, DOI: 10.1007/s40495-017-0088-z.
16. Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea D, Myers JR, Ashton JM, Becker MS, Vasiliou V. Humphries KR, Jordan CT and Smith CA. Targeted therapy for a subset of acute myeloid leukemia’s that lack expression of aldehyde dehydrogenase 1A1. **Haematologica**, 159053, 2017, PMID:28280079.
17. Matsumoto A, Arcaroli J, Chen Y, Gasparetto M, Neumeister V, Thompson DC, Singh S, Smith C, Messersmith W, Vasiliou V. Aldehyde dehydrogenase 1B1: a novel immunohistological marker for colorectal cancer. **Br J of Cancer**, 17:1537-1543, 2017, PMID: 28881356.
18. Charkoftaki G, Jester J, Thompson D, Vasiliou V. Nitrogen mustard-induced corneal injury involves the sphingomyelin-ceramide pathway. **Ocul Surf.** 16:154-162, 2018, PMID: 29129753.
19. Johnson CH, Athersuch TJ, Gwen W. Collman GW, Dhungana S, David F. Grant, Dean P. Jones DP, Patel CJ, Vasiliou V. Yale School of Public Health Symposium on Lifetime Exposures and Human Health: The Exposome; Summary and Future Reflections. **Hum Genomics** 11: 32, 2017, PMCID: PMC5723043.
20. Rattray NJW, Deziel NC, Wallach JD, Khan SA, Vasiliou V, Ioannidis JPA, Johnson CH. Beyond genomics: Understanding exposotypes through metabolomics. **Hum Genomics** 12: 4, 2018, PMID: 29373992.
21. Yang S-M, Martinez NJ, Yasgar A, Danchik C, Wang Y, Baljinnyam B, Wang A, Xu X, Hughes E, Shah P, Cheff D, Wang X, Roth J, Lal-Nag M, Vasiliou V, Simeonov A, Jadhav A, Maloney DJ. Discovery of orally bioavailable, quinoline-based aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with potent cellular activity. **Med Chem,** 61:4883-4903, 2018, PMID: 29767973.
22. Inayat-HussainSH, Fukumura M, Aziz MA, Jin CM, Jin LW, Rolando Garcia-Milian R, Vasiliou V, Deziel NC. Prioritization of Reproductive Toxicants in Unconventional Oil and Gas Operations Using a Multi-Country Regulatory Data-Driven Hazard Assessment. **Environment International,** 117:348-358, 2018, PMID: 29793188.
23. Chen Y, Han M, Matsumoto A, Wang Y, Thompson DC, Vasiliou V, Glutathione and Transsulfuration in Alcohol-Associated Tissue Injury and Carcinogenesis. **Adv Exp Med Biol.** 1032:37-53, 2018.
24. Marshall S, Chen Y, Singh S, Berrios-Carcamo P, Heit C, Nicholas Apostolopoulos N, Golla JP, Thompson DC, Vasiliou V. Engineered animal models designed for investigating ethanol metabolism, glutathione homeostasis toxicity and cancer. **Adv Exp Med Biol.** 1032:203-22, 2018.
25. Lian G, Gnanaprakasam JNR, Wang T, Wu R, Chen X, Liu L, Shen Y, Yang M, Yang J, Chen Y, Vasiliou V, Douglas R. Green DR, Liu Y, Wang R. Glutathione de novo synthesis but not recycling process coordinates with glutaminolysis to control redox homeostasis and directs T cell differentiation. eLife 7:e36158, 2018, PMCID: PMC6152796.
26. Perkins AN, Deziel NC, Inayat-Hussain SH, Johnson CH, Stephen S. Ferguson SS, BoylesAL, Thompson DC, Vasiliou V. Evaluation of Potential Carcinogenicity of Chemicals in Synthetic Turf Crumb Rubber. **Environmental Res**, 169:163-172, 2019, PMID: 30458352.
27. Akiko Matsumoto A, Ito S, Wakamatsu K, Ichiba M, Vasiliou V, Akao C, Song BJ, Fujita M. Ethanol induces skin hyperpigmentation in mice with aldehyde dehydrogenase 2 deficiency. **Chemico-Biol Interactions**, 302:61-66, 2019, PMID: 30721697
28. Charkoftaki G; Wang Y; McAndrews M; Bruford EA; Thompson DC; Vasiliou V, Nebert DW. Update on the human and mouse lipocalin (LCN) gene family, including evidence the mouse Mup cluster is result of an “evolutionary bloom”. **Human Genomics**, 13:11, 2019, PMID: 30782214.
29. Chen Y, Golla S, Garcia-Milan R, Thompson DC, Gonzalez FJ, Vasiliou V. Hepatic Metabolic Adaptation in a Murine Model of Glutathione Deficiency, **Chemico-Biol Interactions**, *303:1-6, 2019*, PMID: 30794799.
30. Charkoftaki G, Thompson DC, Garcia-Milian R, Golla JP, Lam TK, Jasper Engel J, Vasiliou V. Integrated multi-omics approach reveals a role of ALDH1A1 in lipid metabolism in human colon cancer cells. **Chemico-Biol Interactions,** *in press*.
31. Chen Y, Manna SK, Golla S, Krausz KW, Cai Y, Garcia-Milian R, Chakraborty T, Chakraborty J, Chatterjee R, Thompson DC,Gonzalez FJ, Vasillou V. Glutathione deficiency-elicited reprogramming of acetyl-CoA metabolic flux protects against alcohol-induced steatosis, **Free Radic Med Biol**, *in revision*.
32. Kant S, Davuluri G, Alchirazi K, Heit C, Kumar A, Gangadhariah M, McMullen M, Nagy N, Vasiliou V, Marini AM, Weiner D, Dasarathy S. Ethanol sensitizes skeletal muscle to ammonia-induced molecular perturbations, **J Biol Chem**, *revision submitted*.
33. Wang Y, Garcia-Milian R, Thompson DC, Charkoftaki G, Lam TM, Vasilis Vasiliou V. Proteomic profiling of human colon cancer cells reveals a potential regulatory role of aldehyde dehydrogenases in cell proliferation and energy metabolism. **Chemico-Biol Interactions,** *in revision*.
34. Alofe O, Kisanga E, Inayat-Hussain S, Fukumura M, Garcia-Milian R, Perera L, Vasiliou V, Whirledge S. Determining the endocrine disruption potential of industrial chemicals using an integrative approach: public databases, in vitro exposure, and modeling receptor interactions, **Environment International**, *in revision*.

**In preparation**

1. Kurniawan H, Franchina DG, Grusdat M, Nonnenmacher Y, Bonetti L, Guerra L, Hunewald O, Dostert C, Binsfeld C, Duncan G, Farinelle S, Haight J, Gupta D, Taskesen R, Halder R, Ying Chen Y, Ollert M, Wilmes P, Vasiliou V, Harris I, Knobbe-Thomsen CB, Mak TW, Lohoff M, Hiller K, Brenner D. Glutathione controls FoxP3 expression andT regulatory cell metabolism to prevent autoimmunity.
2. Babcock HE, Dutta S, Alur RP, Blain DM, Brocker C, Vasiliou V, Wiggs EM, Pierson TM, Smith AC, Venditti CP, Brooks BP. Ophthalmic anomalies and dysmorphic features found in family with 5q microdeletion, **Human Genomics, in revision.**
3. Heit C, Zakhari S, Thompson DC, and Vasiliou V. Oxidative and Non Oxidative Effects of Ethanol, to be submitted to **Pharmacological Reviews**.
4. HeitC, SabaL, Thompson DC, FritzKS, Vasiliou V. Catalase, Cyp2e1, and Catalase/Cyp2e1 double knockout mice have altered alcohol-drinking preferences. To be submitted to **Alcoholism Clinical Experimental Research**.

**Book Chapters**

1. Vasiliou V, Athanasiou K, Marselos M. The use of ALDH induction as a carcinogenic risk marker in comparison with a typical in vitro system. *In: "Biologically Based Methods for Cancer Risk Assessment*", *C.C.* Travis (ed), New York: Plenum Press, 159: 231-240, 1988.
2. Pappas P, Vasiliou V, Karageorgou M, Marselos M. Changes on the inducibility of a hepatic aldehyde dehydrogenase after treatment with a glutathione depletor. *In: "Alcoholism: A Molecular prespective" (Ed. T.N. Palmer). Plenum Press, New York,* pp. 115-120, 1991.
3. Sophos NA, Black W, Vasiliou V. An update of the ALDH gene superfamily. In *“Enzymology and Molecular Biology of Carbonyl Metabolism”* (Eds. H. Weiner, R. Lindahl, E. Maser, B.V. Plapp), Purdue University Press, pp. 3-7, 2005.
4. Estey T, Lassen N, Pappa A, Vasiliou. ALDH3A1is a multifunctional protein that protects against oxidative damage. In *“Enzymology and Molecular Biology of Carbonyl Metabolism”* (Eds. H. Weiner, R. Lindahl, E. Maser, B.V. Plapp), Purdue University Press, pp. 50-55, 2005.
5. Deitrich RA, Petersen D, Vasiliou V. Removal of acetaldehyde from the body. Novartis Found Symp. 285:23-40, 2007.
6. Marchitti SA, Bateman BJ, Petrash JM, Vasiliou, V, Mouse models of the cornea and lens: understanding ocular disease. In Animal Models for Eye Research, Panagiotis A. Tsonis editor. Elsevier Publisher, pp. 148-165, 2008.
7. Vasiliou V, Petersen DR. Aldehyde dehydrogenases, in *Comprehensive Toxicology* (C. McQueen ed.). Elsevier, ISBN: 978-0-08-046884-6, 2010.
8. Zakhari S, Radaeva S, Vasiliou V. Hepatic and Extrahepatic Malignancies in Alcoholic Liver Disease, in *Alcoholic and Non-Alcoholic Fatty Liver Disease*, (N. Chalasani, G. Szabo eds.), DOI 10.1007/978-3-319-20538-0\_13, Springer International Publishing, Switzerland 2016.
9. Vasiliou, V., Thompson, D. C., Petersen, D. R., 2018. Aldehyde Dehydrogenases, In: McQueen, C. A., Comprehensive Toxicology, Third Edition. Oxford: Elsevier Ltd., Vol. 10, pp. 146-163, 2018.

**Books**

**Alcohol and Cancer (**Zakhari S, Gao B, Vasiliou V eds). Springer 2011, ISBN 978-1-4614-0039-4.

**Biological Basis of Alcohol-Induced Cancer** (Vasiliou V, Zakhari S, Seitz HK; Hoek JB eds), Adv Exp Med Biol Vol 815, Springer 2015. ISBN: 978-3-319-09613-1.

**Alcohol and Cancer - Proceedings of the Third International Conference** (Vasiliou V, Zakhari S, Seitz HK, Mishra L), Springer, Adv Exp Med Biol, in press.

**Editorials**

* 1. Vasiliou V. **Hum Genomics**, 3: 1-2, 2008. PMCID: PMC3525182.
  2. Vasiliou V. **Hum Genomics,** 3: 101-102, 2009, PMCID: PMC3525275.
  3. Vasiliou V.**Hum Genomics**, 3: 211-212, 2009, PMCID: PMC3500191.
  4. Vasiliou V.**Hum Genomics**, 4:1, 2009, PMCID: PMC3500184.
  5. Vasiliou V.**Hum Genomics**, 5:137, 2011, PMCID: PMC3500168.
  6. Vasiliou V.**Hum Genomics**, 5:419, 2011, PMCID: PMC3525968.
  7. Vasiliou V, Nebert DW, A new home for Human Genomics, **Hum Genomics** 6(1): 2012, PMCID: PMC3437565.
  8. Ku CS, Vasiliou V, Cooper DN. A new era in the discovery of de novo mutations underlying human genetic disease. **Hum Genomics** 6(1):27, 2012, PMCID: PMC3538533.